At this year’s EURETINA congress, we caught up with Dr Pravin Dugel to discuss neovascular age-related macular degeneration (nAMD). Dr Dugel suggests that while there have been recent advances in the treatment of nAMD, there is still a need to obtain better efficacy and find drugs that maintain visual acuity improvement over the… Read More »
Lausanne, Switzerland, September 24th, 2018 – Oculis, a clinical-stage biotechnology company developing next-generation topical treatments for acute and chronic back- and front-of-the-eye diseases, announces the appointment of Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board (SAB). Dr. Dugel is internationally recognized for his research in the field of ophthalmologic diseases and brings… Read More »
PALO ALTO, Calif., Aug. 31, 2018 /PRNewswire/ — Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced that enrollment of patients in the company’s phase 1 safety and tolerability study has been completed. First patient in was dosed on July 12, 2018 and last patient… Read More »
We are pleased to share that the first patient in Kodiak’s phase I trial was treated by Dr. Pravin Dugel of the Retinal Consultants of Arizona. The injection was uneventful. Day 2 assessment was within normal limits with no signs of inflammation and with clear ocular media. Kodiak is A Phase I Open Label, Multi-center… Read More »
Dr. Derek Kunimoto visits the AZTV studios to discuss CentraSight’s Implantable Telescope for people with end-stage macular degeneration (wet and dry). For more information, call 602-222-2221 or visit www.CentraSight.com. Age-related macular degeneration (AMD) is the most common cause of severe vision loss in patients over 65. This condition involves a breakdown of the macula, the central… Read More »
Dr. Pravin U. Dugel – Ocular Surgery News U.S. Edition, June 25, 2018 Unmet needs and new options There are unmet needs for DME, mainly related to the high rate of poor responders and the burden of frequent injections. “There are still patients that have suboptimal improvement, so better efficacy is still an unmet need.… Read More »
According to the American Academy of Ophthalmology, approximately 37 million adults in America have age-related macular degeneration, cataract, diabetic retinopathy, or glaucoma, all of which can cause visual impairment or blindness. However, recent studies show that making healthy choices and getting regular eye exams can help reduce a person’s risk of vision loss. In support… Read More »
Pravin U. Dugel, MD, discusses the HAWK and HARRIER studies, particularly with regard to whether the disease activity assessment done at week 16 can predict which patients can be extended to 12 weeks. He also explains why this is important from a clinical standpoint. Interview from the 2018 ARVO Annual Meeting where leading experts recap… Read More »
HONOLULU — The recent HAWK and HARRIER trials of Novartis’ brolucizumab for the treatment of neovascular age-related macular degeneration has helped researchers predict which patients will need an 8-week dosing regimen or a 12-week regimen with an almost 90% predictability rate, Pravin Dugel, MD, said at the Association for Research in Vision and Ophthalmology meeting… Read More »
The use of the anti-VEGF agent ranibizumab for the treatment of neovascular age-related macular degeneration (nAMD) in patients aged 85 and over does not increase a patient’s risk of systemic serious adverse events (SAEs) like heart attack or stroke. Although the study, led by Pravin Dugel, MD, a clinical professor with the University of Southern… Read More »
